(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Shire CEO Flemming Ornskov on the outlook for the company after getting FDA approval for Xiidra drops to treat dry-eye disease.

Meta to Spend Up to $27 Billion on Nebius AI Infrastructure
15:55

Adobe CEO to Step Down in Face of Investor Concerns Over AI
18:19

Dick’s Projects Sales Growth at Namesake Stores, Foot Locker
14:01